What Ventipulmin for Horses Treats: Main Uses and Benefits

The primary purpose of this veterinary medicine may be part of symptomatic management in horses experiencing conditions that affect normal breathing. It is applied across therapeutic domains where additional symptomatic support is needed to address airway obstruction.

The medicine is commonly used to help with symptoms related to heightened physiological activity in the lower airways. These include managing the episodic manifestations of coughing, easing distress related to labored breathing, and easing functional symptoms that interfere with daily movement. It is relevant in contexts involving conditions characterized by periods of heightened symptoms, such as Recurrent Airway Obstruction (RAO or Equine Asthma), certain chronic respiratory allergies, and other obstructive respiratory infections.

“It provides supportive relief when symptoms create noticeable physiological strain during movement and routine activities.”

---

Quick Fact: Relief for Respiratory Strain

By assisting with maintaining functional stability, this supportive management contributes to symptomatic comfort during periods when symptoms are more noticeable, especially when physical exertion is involved.

Regulatory References

1. UK Veterinary Medicines Directorate (VMD) Summary

Eligibility Map: Who can and cannot use Ventipulmin for Horses

Ventipulmin (Clenbuterol hydrochloride) is approved for use in horses affected with airway obstruction, such as occurs in Chronic Obstructive Pulmonary Disease (COPD). Official regulatory documents define strict exclusions for specific populations and conditions.

---

Populations for whom use is Contraindicated (Must Not Be Used):

• Horses with known cardiac disease or suspected cardiovascular impairment (due to the potential for tachycardia).
• Horses with a known hypersensitivity to the active ingredient, Clenbuterol hydrochloride.
• Pregnant mares near term, as the drug may antagonize the effects of oxytocin and abolish uterine contractions.

---

Eligibility-Related Restrictions:

• Food Safety Prohibition: The drug is prohibited for use in horses intended for human consumption.
• Reproductive Status: The effect on reproduction has not been determined in breeding stallions and brood mares, according to the official label.
• Age/Organ Function: Official labeling does not state specific population restrictions based on age (e.g., foals) or organ function (hepatic/renal impairment).

Interaction Map: Interactions with other medicines and products — official regulatory information for Ventipulmin for Horses

Interaction scope

Property	Official Regulatory Information
Medicinal product categories with documented interactions	beta-Adrenergic Blocking Agents; Uterine Stimulant Agents (Prostaglandins, Oxytocin); General Anaesthetics (Halogenated Agents); Other Sympathomimetic Amines; Corticosteroids.
Specific interacting medicines (if explicitly listed)	Prostaglandin F2alpha; Oxytocin; Halogenated General Anaesthetics; beta-blockers.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic antagonism (with beta-blockers and Uterine Stimulants); Additive cardiovascular effects (with Sympathomimetic Agents); Increased cardiac risk (with Halogenated Anaesthetics).
Timing-based interaction rules (if applicable)	Discontinuation is required prior to general anesthesia or at the expected time of delivery.
Population-specific interaction notes (if applicable)	The medicine must not be used in pregnant mares near term.
Interaction-related restrictions	Co-administration with beta-adrenergic blocking agents is formally opposed. Concurrent use with corticosteroids is not recommended.

---

Interaction classifications (high-level)

Property	Official Regulatory Information
Interaction severity classification (as defined in official documents)	Contraindicated (with beta-blockers); Restriction/Warning (with Anaesthetics, Uterine Stimulants); Not Recommended (with Corticosteroids).
Regulatory basis (EMA / FDA / etc.)	Established by government and veterinary medicines authorities.
Interaction-context constraints (as defined in official documents)	Applies when co-administering drugs with opposing or additive beta-adrenergic effects.

---

Resulting interaction structure

Official interaction statements:

• Co-administration with beta-adrenergic blocking agents is officially opposed due to complete pharmacodynamic antagonism of the drug's effect. • Clenbuterol antagonizes the effects of uterine stimulants, specifically Prostaglandin F2alpha and Oxytocin. • Due to the antagonism of uterine stimulants, regulatory labels require that this medicine must not be used in pregnant mares near term. • The use of Halogenated General Anaesthetics must be considered a procedural constraint due to the risk of increased cardiac effects. • Concurrent use of Corticosteroids is not recommended due to a potential risk of increasing peripheral vasodilating effects.

Connection to the overall interaction profile:

The official regulatory profile is defined by pharmacodynamic conflicts, focusing on the mandatory restriction against beta-blockers and the antagonism of uterine stimulants. The structure highlights the necessity of discontinuing the medicine before specific medical procedures or in particular populations where the interaction could result in a significant physiological conflict.

How Ventipulmin for Horses Works

Clenbuterol hydrochloride's mechanism is initiated by its function as a selective agonist at beta2-adrenoceptors on airway smooth muscle cells. This targeted interaction triggers a profound intracellular cascade via the Gs protein.

The cAMP-Mediated Relaxation Cascade

Receptor activation stimulates adenylyl cyclase, leading to an increase in intracellular cyclic AMP (cAMP). This rise in cAMP activates Protein Kinase A (PKA), which subsequently causes the functional inhibition of Myosin Light Chain Kinase (MLCK). This biochemical chain reaction is the mechanism that causes the physical relaxation of the bronchial smooth muscle, resulting in a reduction in pulmonary resistance.

Modulation of Mediator Release and Mucociliary Function

Beyond bronchodilation, the mechanism extends to modulating immune and epithelial cells. This involves inhibiting the release of pro-constrictive mediators (e.g., histamine) and increasing ciliary beat frequency. This dual action causes a reduction in pro-constrictive mediator release and enhances the clearance of mucus and secretions, which influences airflow dynamics.

The use of Ventipulmin (Clenbuterol hydrochloride) in horses is governed by specific instructions concerning administration route, dosage titration, and treatment duration.

Administration Route, Forms, and Frequency

The medicine is supplied as an oral syrup and is administered exclusively via the oral route. Dosing follows a twice-daily (b.i.d.) schedule, which ensures consistent delivery. The active strength varies by preparation, with concentrations of 72.5 mcg/mL or 25 micrograms/mL utilized. Administration techniques also vary; for instance, delivery may occur using a plastic dispensing cap and syringe for direct administration, or the syrup may be added to the feed.

Labeled Dosing and Procedural Schedule

Dosing is determined based on the horse’s body weight (kilograms or pounds). The standard initial dose is 0.8 micrograms per kilogram body weight. The administration follows a step-wise approach if needed, involving escalating the dose incrementally. Each new level is administered for 3 days (6 treatments), up to a maximum dose of 3.2 mcg/kg.

Course Duration and Use Constraints

The recommended duration of treatment at the established effective dose is typically 30 days. Following this period, the medication should be withdrawn to assess for recurrence of signs. If signs reappear, the full step-wise dosage schedule must be repeated upon reinstitution of treatment. The product is designated for use only in horses not intended for human consumption (non-food animal use).

Research Evidence / Overview of Studies

Evaluating Mechanism of Action

Research was designed to examine the compound's interaction with specific target receptors. The research explored whether the compound was associated with changes in patient-reported outcomes, specifically to investigate the compound's effect on pain measures and the onset of action. Preliminary findings were reported that describe the compound's actions within certain biological pathways.

---

Clinical Trials and Observed Effects

Research has been conducted to determine the effects of this compound. Multiple studies have examined the compound's effects in individuals with moderate-to-severe chronic conditions.

• Phase II Trials: Early-phase studies, primarily focusing on dosage, were designed to assess the compound’s effects when used for a limited duration. Researchers recorded various study endpoints related to safety and participant toleration.
• Phase III Trials: Larger, randomized, controlled trials focused on the primary outcome measure, which focused on symptom severity changes. These studies also examined secondary outcomes, investigating whether the compound was associated with changes in inflammatory markers over time.

In trials comparing the compound to existing options, researchers recorded different outcome measures. The results showed variations in how different patient groups responded to the compound, and further analysis is underway to clarify the applicability of these findings.

---

Combined Therapy Research

Studies evaluated the effect of the combination on symptom scores when the compound was administered alongside a standard care regimen. The research focused on whether the combined approach resulted in different outcomes compared to the standard regimen alone. Data on adverse event rates for both monotherapy and combination therapy were also collected and analyzed.

Research has evaluated this compound to provide initial findings regarding the compound. Evidence remains limited, and it is not yet clear whether these results will translate into long-term changes for all individuals.

Key Studies & References

1. FOI Summary for Original Approval of NADA 140973 May 11 1998 - Ventipulmin® Syrup (clenbuterol hydrochloride) (FDA)
2. Clenbuterol and the Horse (AAEP Proceedings/Ivis.org)

Common questions about Ventipulmin for Horses (FAQ)

Q: What is the shelf-life of Ventipulmin syrup before the bottle is opened?

According to official regulatory documents, the shelf-life of the product when it is in its original, unopened packaging is typically 2 years. This indicates the timeframe the medicine is expected to maintain its properties while sealed, assuming correct storage conditions are met.

---

Q: How quickly does Ventipulmin start working after the first dose?

Studies and official information indicate that the active ingredient, Clenbuterol, usually reaches its maximum concentration in the horse's bloodstream about 2 hours after being given orally. This measurement is used as a regulatory proxy for when the drug's concentration is highest in the bloodstream.

---

Q: Is there an injection or IV form of Clenbuterol for horses?

While Ventipulmin is typically supplied as an oral syrup, official regulatory databases in some regions do list a Solution for Injection containing Clenbuterol hydrochloride as an authorised veterinary medicinal product for horses. The prescribing veterinarian determines the appropriate product form.

---

Q: Does Ventipulmin require a veterinary prescription?

Yes, official regulatory documents, including those from the FDA, classify Ventipulmin as a Prescription Animal Drug. Official regulations indicate that its use is restricted to authorization by a licensed veterinarian.

Storage and Disposal Requirements

Official regulatory documentation mandates specific environmental and handling conditions for storing Ventipulmin Syrup. The product must be stored at a temperature at or below 25 C (77 F), with US labeling specifying Controlled Room Temperature (15 C to 30 C). It is explicitly required to avoid freezing the medicine.

To ensure quality, the syrup must be protected from light, and the safety cap must be replaced when the bottle is not in use. After first opening, the product's stability is limited, and it must be used within 30 days, after which any unused portion must be discarded.

For safety, the product must be kept out of the sight and reach of children. All unused or expired product and waste materials must be disposed of in accordance with local requirements and must not be discarded via wastewater.